Effect of Rosiglitazone on In Vitro Pre-Implantation Mouse Embryo Development

Background: Rosiglitazone as an anti-diabetic drug has antiinflammatoryand anticancer properties. Rosiglitazone arehighly selective and potent agonists for the nuclear receptorPeroxisome proliferator-activated receptor gamma (PPARγ),strongly implicated in female reproduction. Rosiglitazone havebeen proposed to exert anti-inflammatory effects because theymay be inhibit secretion pro-inflammatory cytokines such astumor necrosis factor-α (TNF-α) and interleukin ۶. This studyaimed to investigate the effect of rosiglitazone on in vitro preimplantationmouse embryo development.Materials and Methods: ۶-۸ weeks female NMRI mice weresuperovulated with PMSG by intraperitoneal injection, followedby HCG injection and mating after ۴۸ hours. Mice were killedvia cervical dislocation ۱۸ hours post HCG injection. Embryowere then recovered from oviduct ampulla and cultured withand without rosiglitazone (۰, ۱۰, ۲۵, ۵۰, ۷۵ μM). Cleavage andblastocyst rate were assessed. Also, total cell number were assessedwith differential staining.Results: ۱۰ μM rosiglitazone caused the highest cleavage (%۱۰۰) and blastocyst rates (%۵۸.۹۷۹۵) in comparison to otherconcentrations (۲۵, ۵۰, ۷۵ μM) but not significant with control.Also, there is no significant difference in the total cell numberbetween control and rosiglitazone groups. Blastocyst quantityand quality reduced in ۵۰, ۷۵ μM groups in comparison to control.Conclusion: These data provide evidence that PPARγ can be akey target for embryo development and high concentration ofPPARγ agonist (rosiglitazone) is toxic.

کلیدواژه ها:

Mouse ، Rosiglitazone ، Blastocyst ، PPARγ